Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
Cytolytic T lymphocyte (CTL) responses were evaluated in humans immunized with recombinant human immunodeficiency virus type 1 (HIV) envelope glycoprotein gp160. Some vaccinees had gp160-specific CTLs that were shown by cloning to be CD4+. Although induced by exogenous antigen, most gp160-specific CTL clones also recognized gp160 synthesized endogenously in target cells. These clones lysed autologous CD4+ T lymphoblasts infected with HIV. Of particular interest were certain vaccine-induced clones that lysed HIV-infected cells, recognized gp160 from diverse HIV isolates, and did not participate in "innocent bystander" killing of noninfected CD4+ T cells that had bound gp120.
Orentas
R J
RJ
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Hildreth
J E
JE
Obah
E
E
Polydefkis
M
M
Smith
G E
GE
Clements
M L
ML
Siliciano
R F
RF
D002478:Cells, Cultured; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic; D015686:Gene Products, env / Q000276:immunology*; D006678:HIV / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D006679:HIV Seropositivity; D006801:Humans; D007114:Immunization; D046911:Macromolecular Substances; D011498:Protein Precursors / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D046911:Macromolecular Substances; D011498:Protein Precursors; D011994:Recombinant Proteins; D014765:Viral Vaccines